Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment
Article in Vaccine (June 2022)
The most recent citing publications are shown below. View all 89 publications that cite this research output on Dimensions.
Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector–based COVID‐19 vaccine
Article in Immunological Reviews (June 2022)
Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study
Article in Vaccine (June 2022)